SCHEMBL2179988

SCHEMBL2179988

COc1cccc(NC(=O)Nc2ccc(-c3ccc4c(c3)CN(C(C(=O)O)C(C)C)C4=O)cc2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 2/20 0.53
TP53 P04637 3/20 0.53
LMNA P02545 2/20 0.53
TSHR P16473 1/20 0.48
KDR P35968 1/20 0.48
NPC1 O15118 4/20 0.45
RAB9A P51151 4/20 0.45
CASP3 P42574 1/20 0.45
SENP7 Q9BQF6 1/20 0.45
CNR1 P21554 1/20 0.45
MAPT P10636 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MAPK1 P28482 1/20 0.44
STAT1 P42224 1/20 0.44
HTT P42858 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
CLK1 P49759 1/20 0.44
MITF O75030 1/20 0.43
ALDH1A1 P00352 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2181456 1.00 DGAT1 (0.53) DGAT1TP53LMNATSHRKDR
SCHEMBL2177510 0.93 LMNA (0.52) DGAT1TP53LMNANPC1MAPT
SCHEMBL2177019 0.93 LMNA (0.52) DGAT1TP53LMNANPC1MAPT
SCHEMBL2177471 0.93 TP53 (0.53) DGAT1TP53LMNATSHRKDR
SCHEMBL2178942 0.93 TP53 (0.53) DGAT1TP53LMNATSHRKDR
SCHEMBL2180785 0.92 LMNA (0.60) DGAT1TP53LMNANPC1RAB9A
SCHEMBL2178532 0.92 LMNA (0.60) DGAT1TP53LMNANPC1RAB9A
SCHEMBL2181226 0.90 LMNA (0.51) DGAT1TP53LMNAMAPTTHRB
SCHEMBL2179718 0.90 LMNA (0.51) DGAT1TP53LMNAMAPTTHRB
SCHEMBL2178233 0.88 DGAT1 (0.52) DGAT1TP53LMNAKDRSDCBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT DGAT1 1/4885TP53 2093/4885LMNA 2193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.